Latest Humanized antibody Stories
INCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that all shareholders owning shares of PDL on September 17, 2009, will be paid a dividend of $0.50 per share on October 1, 2009.
INCLINE VILLAGE, Nev., May 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P.
MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc.
SAN DIEGO, Feb.
New data demonstrates that Angiolix has similar efficacy to Avastin alone and in combination with other chemotherapeutics, with potentially less side-effects; study validates results seen in Previous Breast Cancer Model DALLAS, Jan. 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire/ -- Based on its recent analysis of the ophthalmic pharmaceuticals market, Frost & Sullivan recognizes ESBATech with the 2009 North American Frost & Sullivan Technology Innovation of the Year Award for its work in developing antibody fragments.
SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
MORRIS PLAINS, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L.
BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr.
MORRIS PLAINS, N.J., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Gerard G.
- One who brings meat to the table; hence, in some countries, the official title of the grand master or steward of the king's or a nobleman's household.